• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

    15.20 -0.86 (-5.35%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 13, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,081,444
    Open 16.19
    Bid (Size) 15.21 (1)
    Ask (Size) 15.93 (10)
    Prev. Close 16.06
    Today's Range 15.01 - 16.28
    52wk Range 8.580 - 22.50
    Shares Outstanding 69,484,053
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +8.0%
    +8.0%
    1 Month
    -2.3%
    -2.3%
    3 Month
    +54.3%
    +54.3%
    6 Month
    +35.2%
    +35.2%
    1 Year
    -23.3%
    -23.3%

    More News

    Read More
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    Earnings Scheduled For August 4, 2025
    Via Benzinga
    Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth
    Via Benzinga
    This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
    Via Benzinga
    Deep Dive Into Syndax Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)
    Via Benzinga
    Syndax Announces Participation in September Investor Conferences
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    Syndax Pharmaceuticals's Earnings: A Preview
    Via Benzinga
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    Syndax (SNDX) Q2 Revenue Jumps 986%
    Via The Motley Fool
    Topics Intellectual Property
    Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Reports Mixed Q2 2025 Earnings with Revenue Beat and Narrower EPS Loss
    Via Chartmill
    Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    Syndax Announces Participation in June Investor Conferences
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    Let's uncover which stocks are experiencing notable gaps during today's session.
    Via Chartmill
    Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire
    Syndax Announces Participation in May Investor Conferences
    From Syndax Pharmaceuticals, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Syndax Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Syndax Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Syndax Pharmaceuticals, Inc. - Common Stock trade on?
    Syndax Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock is SNDX on the Nasdaq Stock Market
    What is the current price of Syndax Pharmaceuticals, Inc. - Common Stock?
    The current price of Syndax Pharmaceuticals, Inc. - Common Stock is 15.20
    When was Syndax Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Syndax Pharmaceuticals, Inc. - Common Stock was at 10/13/25 04:00 PM ET
    What is the market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock is 1.06B
    How many shares of Syndax Pharmaceuticals, Inc. - Common Stock are outstanding?
    Syndax Pharmaceuticals, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.